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Abstract
Genome-wide association studies (GWAS) have quickly become the norm in dissecting the genetic
basis of complex diseases. Family-based association approaches have the advantages of being robust
to possible hidden population structure in samples. Most of these methods were developed with
limited markers. Their applicability and performance for GWAS need to be examined. In this
report, we evaluated the properties of the family-based association method implemented by
ASSOC in the S.A.G.E package using the simulated data sets for the Framingham Heart Study, and
found that ASSOC is a highly useful tool for GWAS.

Background
Genome-wide association studies (GWAS) are gaining
popularity in genetic analysis of complex traits with the
development of genotyping technology at the genome
level. With genetic information at millions of singlenucleotide polymorphisms (SNPs) and other genetic
markers, such studies offer great opportunities and also
present challenges in developing appropriate statistical
analysis methods. The data distributed by Genetic
Analysis Workshop 16 provides a great opportunity to
examine the strengths and limitations of current statistical methods for GWAS.
Many GWAS have been reported in the literature and
many more are being performed. Most of them are
population-based association studies and use designs

such as case-control studies. Such designs have the
advantages that samples are easy to ascertain and that
results have relatively high power when analyses are
carried out properly. However, it has been shown that
population-based approaches, such as case-control studies, can produce spurious associations in the presence
of population substructure, especially in large-scale
studies at the genomic level [1,2]. An alternative
approach is to use the family-based association methods,
such as the transmission-disequilibrium test [3], the
family-based association test (FBAT) [4], and a regression method [5] implemented by ASSOC in the S.A.G.E.
package. These methods are robust to population
substructure and other cryptic relatedness in the samples.
However, these methods have been proposed in the era
with only a few genetic markers and are intended mostly
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for candidate-gene studies. Their applicability and
performance for GWAS has not been examined. The
simulated data set of the Framingham Heart Study (FHS)
provides both the family structure and the genotype
information at genome-wide SNPs. The underlying
simulation models are also provided. It is the purpose
of this study to evaluate the performance of the familybased association method implemented by ASSOC in
analyzing GWAS.

Methods
ASSOC implements a regression method that tests for
association between a continuous trait and one or more
covariates, including genetic markers from extended
family data, and accounts for familial correlations [5].
The program estimates the parameters of a baseline
model and those of alternate models that include
specific sets of covariates. A likelihood-ratio test is then
performed to evaluate the significance of the covariates.
The FHS simulated data set includes 6,476 subjects with
both phenotype and genotype data in 942 pedigrees of
up to three generations and 188 singletons. We excluded
the singletons from our analysis because they do not
have family information. The simulated data contain
200 replicates of the phenotypes. We used the phenotype
data from the first replicate. Pedigree files were constructed from the supplied ‘triplet_sim’ file and merged
with phenotype and genotype data. In addition to each
of the SNPs, we included subject’s age, smoking status,
diet, and lipid-lowering drug usage as covariates. We
kept all family members in the analysis because ASSOC
could account for the familial correlations. We chose to
test the association of HDL with all the makers from
chromosome 19 in the 50 k panel and 500 k panel
because there are two major genes for HDL on
chromosome 19. In all, there are 1,639 markers in the
50 k panel and 6,350 markers on 500 k panel on
chromosome 19. We assumed an additive model for all
the markers. The program was run in a batch mode so
that it would test for the association of the SNPs
successively in one run. From the simulation model,
there are five major genes for HDL. Two were on
chromosome 19, and the other three were from

chromosomes 8, 9, and 15, respectively. The chromosome locations of the five major genes were given in
Table 1. We tested the association of HDL with all the
five major genes. There are a total of 1,000 polygenes for
HDL, among which 15 are on chromosome 19.

Results
We performed association tests of all 1,639 markers on
chromosome 19 with simulated HDL data. Out of 1,639
markers, the tests of 18 markers were significant at the
0.01 level. Because the HDL data were simulated using
the markers in the 500 k panel and not the markers in
the 50 k panel, and since the markers in the two panels
are not close, we assume that the markers in the 50 k
panel did not contribute to the HDL phenotype. The
significance result reflects false positives. Therefore, our
results give an empirical type I error probability of 0.011,
which agrees well with the nominal level of 0.01.
We further tested the association of the five SNPs
representing the major genes with HDL (Table 1). They
were all significant at 0.05 level regardless of the mode of
inheritance and heritability. The true genetic models are
additive for rs8103444, rs8035006, and rs8192719, and
dominant for rs10820738 and rsrs3200218. However, if
more stringent significance level were used for genomewide studies, only two markers, rs10820738 and
rs3200218, were found significant at 10-6 level. Table 1
also gives the estimated effect size for the five SNPs. SNP
rs10820738 has the largest effect size, which is consistent
with the simulation model in which it has the largest
heritability.
We then tested all 6,350 SNP markers on chromosome
19 in the 500 k panel for association with the simulated
HDL data. Among the 15 markers that have polygenic
effects on chromosome 19, association tests at six
markers were significant at the 0.05 level (Table 2). The
marker positions in base pairs are also given in Table 2.
The pairwise LD was relatively low, with a maximum r2
of 0.003 as computed with Haploview [6]. A total of 395
tests were significant at 0.05 level for all the 6,350
markers tested on chromosome 19. Excluding the two
major genes and six polygenes that are truly associated

Table 1: Test results of the 5 SNPs from 500 k panel for major gene effects of HDL

Model
rs10820738
rs3200218
rs8035006
rs8192719
rs8103444
a

Location

Intercept

Diet

Sex

Rxa

Age

Smokeb

SNP

SE

p-Value

9q31.1
8p22
15q21
19q13.2
19113.2

68.694
68.680
68.684
68.689
68.686

0.028
0.027
0.023
0.021
0.021

13.565
13.552
13.527
13.524
13.533

1.486
1.420
1.474
1.470
1.452

0.019
0.020
0.020
0.020
0.019

0.714
0.664
0.647
0.666
0.660

4.524
-1.671
0.831
-0.821
0.629

0.518
0.319
0.284
0.306
0.305

3.20 × 10-18
1.63 × 10-7
0.003
0.007
0.039

Rx, lipid lowering drug use.
Smoke, smoking status.

b
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Table 2: Test results among polygenes affecting HDL on chromosome 19

Model
rs10420985
rs8182590
rs35150881
rs8107007
rs10403702
rs7251886
rs11673050
rs2277987
rs16989305
rs16966229
rs17620029
rs3786501
rs11085876
rs17716486
rs599458
a

Position

Intercept

Diet

Sex

Rxa

Age

Smokeb

62,077,748
13,282,550
2,572,193
33,248,124
44,840,424
46,880,615
35,535,929
8,458,273
49,579,243
36,924,150
24,146,152
49,691,015
13,947,513
34,455,727
20,792,763

68.693
68.691
68.689
68.691
68.692
68.687
68.690
68.689
68.689
68.687
68.690
68.691
68.689
68.690
68.689

0.017
0.029
0.023
0.022
0.021
0.020
0.019
0.021
0.023
0.021
0.019
0.021
0.020
0.020
0.021

13.519
13.542
13.537
13.548
13.532
13.537
13.530
13.549
13.540
13.530
13.539
13.536
13.540
13.539
13.538

1.508
1.478
1.449
1.454
1.491
1.501
1.473
1.480
1.482
1.461
1.465
1.473
1.467
1.478
1.473

0.020
0.019
0.019
0.020
0.020
0.020
0.020
0.020
0.020
0.020
0.020
0.020
0.020
0.020
0.020

0.656
0.686
0.663
0.651
0.647
0.669
0.659
0.658
0.666
0.660
0.652
0.656
0.655
0.655
0.657

SNP
-1.693
-0.973
-1.727
1.683
5.564
-0.666
-0.505
0.496
4.904
-2.165
-0.390
0.217
-0.164
-0.204
0.082

SE

p-Value

0.457
0.263
0.550
0.537
2.199
0.266
0.279
0.289
3.111
1.381
0.369
0.314
0.273
0.376
0.454

0.000214
0.000222
0.0017
0.001723
0.011418
0.012645
0.069854
0.08626
0.115021
0.117801
0.291036
0.490909
0.547852
0.586957
0.856762

Rx, lipid lowering drug use.
Smoke, smoking status.

b

with the trait, this gives an estimated empirical type I
error rate of 0.06. Figure 1 gives the quantile-quantile
plot of the p-values for all the null markers. The observed
distribution fits well with the expected uniform distribution and there is no major inflation of type I error.
Among the top 50 SNPs ranked by p-values, four SNPs
are true findings with polygenic effects.
We also applied FBAT to test the association of HDL with
all 6,350 SNPs on chromosome 19. A total of 325 tests
are significant at 0.05 level. However, only two
polygenes are true positives (rs10420985 and
rs599458, with p-values 0.004408 and 0.028563, respectively). None of the major genes was significant with

Figure 1
Quantile-quantile plot of the p-values from null
markers.

FBAT. Nonetheless, the type I error rate seems well
controlled.

Discussion
Family-based association methods are appealing alternatives for the population-based case-control design
because they are robust to population stratification in
the samples. Several such methods have been proposed.
However, they were all proposed before the current
genomic era. As the norm of the field moves to GWAS,
the performance and applicability of these methods need
to be examined for GWAS. In this report, we examined
the performance of a regression-based method [5],
implemented in the program ASSOC in the software
package S.A.G.E., using the simulated HDL data in the
Framingham Heart Study. Based on the results of the
tests with the markers on chromosome 19 in the 50 k
panel, we found that ASSOC gives the correct type I error
rate. When applied to the markers on chromosome 19 in
the 500 k panel (tests performed at 0.05 level), the
empirical type I error rate was 0.06, which is slightly
inflated. The reason could be that there is linkage
disequilibrium between the markers in the causal genes
and markers close by, and when we estimated type I error
rate, we only excluded the markers in the causal genes
with either major or polygenic effects and not those
markers in linkage disequilibrium. Therefore, as a
general conclusion, ASSOC gives a more-or-less the
correct type I error rate, and hence is a valid test for
GWAS.
In our analysis, ASSOC detected all five major genes and
six of the 15 polygenes for HDL on chromosome 19. In
contrast, FBAT detected only two of the 15 polygenes
and none of the major genes on chromosome 19. It
should be noted that the data may be too limited to give
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a reliable estimation of the power. However, it is
encouraging to see that ASSOC could detect one of the
polygenes, rs10403702, whose minor allele frequency is
only 0.35%. Current association studies generally focus
on common SNPs (e.g., SNPs with minor allele
frequency > 5%) based on the common disease,
common variants hypothesis [7-10]. The other reason
is that the statistical power may not be sufficient for rare
SNPs when the sample size is limited. However, recent
development in genotyping technology allows efficient
genotyping in large samples and there is a call for
shifting the paradigm of association studies to rare SNPs
because it may be more effective to discover susceptibility genes for common diseases [11].

http://www.biomedcentral.com/1753-6561/3/S7/S124

This article has been published as part of BMC Proceedings Volume 3
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Conclusion
Using the simulated data for the Framingham Heart
Study, we found the family-based regression method
George et al. [5] implemented in ASSOC in the S.A.G.E.
software is applicable to GWAS. It provides the correct
type I error rate and reasonable power. However, this
method is computationally time-consuming.
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